803 results on '"Gligorov, Joseph"'
Search Results
2. Why and how citrate may sensitize malignant tumors to immunotherapy
3. Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer
4. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
5. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer
6. Simultaneous quantification of four hormone therapy drugs by LC-MS/MS: Clinical applications in breast cancer patients
7. Association between overweight, obesity, and quality of life of patients receiving an anticancer treatment for prostate cancer: a systematic literature review
8. Feasibility, criterion and construct convergent validity of the 2-minute walk test and the 10-meter walk test in an oncological context
9. Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients’ With HER2-Positive Metastatic Breast Cancer
10. BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors
11. Systemic therapy for early-stage breast cancer: learning from the past to build the future
12. Prediction of moderate and severe toxicities of chemotherapy in older patients with cancer: a propensity weighted analysis of ELCAPA cohort.
13. Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations.
14. Objectifs, motivations et difficultés des internes en phase socle en oncologie
15. Comparison of MetaMap, cTAKES, SIFR, and ECMT to Annotate Breast Cancer Patient Summaries
16. Using Machine Learning and Deep Learning Methods to Predict the Complexity of Breast Cancer Cases
17. Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.
18. Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma
19. How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer
20. Comparaison des caractéristiques et des pronostics des patients avec et sans cancer actif hospitalisés pour une infection à SARS-CoV-2
21. Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring
22. Guide sur le rôle du « Docteur Junior » en oncologie médicale
23. Predicting the likelihood of recurrence of pregnancy-associated breast cancer: Nomogram based on analysis of the French cancer network: Cancer Associé à La Grossesse
24. Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe
25. A retrospective study of patients treated with by oral anticancer drugs: Impact of pharmacy consultation
26. Are Semantic Annotators Able to Extract Relevant Complexity-Related Concepts from Clinical Notes?
27. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023
28. Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associé à La Grossesse) network
29. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic
30. Consultation personnalisée d’évaluation du risque de cancer du sein : premiers résultats
31. Dépistage et diagnostic du cancer du sein à la fin de période de confinement COVID-19, aspects pratiques et hiérarchisation des priorités
32. COVID-19 et personnes suivies pour un cancer du sein : recommandations françaises pour la pratique clinique de Nice-St Paul de Vence, en collaboration avec le Collège Nationale des Gynécologues et Obstétriciens Français (CNGOF), la Société d’Imagerie de la Femme (SIFEM), la Société Française de Chirurgie Oncologique (SFCO), la Société Française de Sénologie et Pathologie Mammaire (SFSPM) et le French Breast Cancer Intergroup-UNICANCER (UCBG)
33. Neglected giant benign phyllode tumor of the breast
34. Reusing Decisions Made with One Decision Support System to Assess a Second Decision Support System: Introducing the Notion of Complex Cases
35. CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion
36. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023
37. IN11 HOW TO OPTIMIZE CARE FOR LONG TERM RESPONDERS: TO BE OR NOT TO BE ON “TREATMENT HOLIDAYS”
38. Creating Synthetic Patients to Address Interoperability Issues: A Case Study with the Management of Breast Cancer Patients
39. Propensity score to evaluate prognosis in pregnancy-associated breast cancer: Analysis from a French cancer network
40. The extracellular domain of Her2 in serum as a biomarker of breast cancer
41. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer
42. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
43. Percutaneous Image-Guided Electrochemotherapy of Spine Metastases: Initial Experience
44. Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics
45. Second-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report
46. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
47. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial
48. Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort
49. Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective
50. Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.